Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 7/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15456206 | 0.82 | LMNA (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL27607474 | 0.80 | LMNA (0.46) | KMT2AMEN1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL27607461 | 0.80 | CYP19A1 (0.44) | KMT2AMEN1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL18255912 | 0.79 | TP53 (0.45) | KMT2AMEN1SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6796094 | 0.78 | SLC6A3 (0.46) | KMT2AMEN1SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6800933 | 0.77 | SIRT1 (0.44) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8198987 | 0.76 | HSD11B1 (0.42) | KMT2AMEN1ALDH1A1MAPTSTAT3 | |
| SCHEMBL3715604 | 0.75 | CA12 (0.42) | ALDH1A1MAPTSTAT3TP53 | |
| SCHEMBL241884 | 0.75 | CA1 (0.52) | KMT2ASMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL18289524 | 0.74 | CA1 (0.50) | KMT2AMEN1ALDH1A1NPC1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | KMT2A 2457/4885MEN1 2426/4885SMN1; SMN2 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.